Deferasirox Patent Expiration
Deferasirox is used for treating allergies and allergic reactions. It was first introduced by Novartis Pharmaceuticals Corp
Deferasirox Patents
Given below is the list of patents protecting Deferasirox, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Jadenu | US9283209 | Oral formulations of deferasirox | Nov 21, 2034 | Novartis Pharms Corp |
| Exjade | US6465504 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Apr 05, 2019
(Expired) | Novartis |
| Jadenu | US6465504 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Apr 05, 2019
(Expired) | Novartis Pharms Corp |
| Jadenu Sprinkle | US6465504 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Apr 05, 2019
(Expired) | Novartis |
| Exjade | US6596750 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Jun 24, 2017
(Expired) | Novartis |
| Jadenu | US6596750 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Jun 24, 2017
(Expired) | Novartis Pharms Corp |
Deferasirox's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Deferasirox:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Early Screening and Treatment of Heart Complication in Sickle Cell Disease | Inova Health Care Services | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation | University of Michigan Rogel Cancer Center | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |